focus -WSS

focus

author：explore 2025-09-27 15:19:21 - browse：767

Brain cancer — Michelle Monje/Stanford University/NIH

Tocagen (TOCA) said Tuesday that a Phase 3 clinical trial involving a novel gene therapy for aggressive brain tumors will continue to a final analysis later this year, following an interim look at patient survival data conducted by independent monitors. Tocagen’s stock price dropped sharply.

The San Diego-based biotech pitched the study’s continuation as an encouraging sign for its gene therapy called Toca 511/Toca FC, which is designed to deliver a localized chemotherapy directly to the site of brain tumors.

“We believe the longer-term follow-up of patients in the final analysis, particularly for those randomized in the second enrollment period, will be important in assessing both primary and secondary endpoints,” said Tocagen CEO Marty Duvall, in a statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： Meadows told special counsel he could not recall Trump ever declassifying Mar

WSS

Pumping milk in bathrooms at health conferences is common

CVS is on a mission to consolidate health care. Will it work?

Readout Newsletter: Parkinson's study, Gilead, CG Oncology

Hospital at home shows how to bring innovation to health care

TikTok, Instagram influencers need more rules for drug ads

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

focus

focus

focus

DIEP, the 'gold standard' of breast reconstruction, is under threat

Medicare drug price lawsuits could be good politics for Biden

Duchenne breakthrough therapy leaves behind pioneering families

High breast density mammograms need follow

Hepatitis C has a cure — but many Americans still lack access to it

Immunocompromised patients offer clues on chronic Covid

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Trump to be booked at notorious Fulton County Jail at center of DOJ probe

FDA approval of Sarepta Duchenne genetic therapy gives me hope

How the drug

focus

Inaction leaves children at risk from dangerous chemotherapy drug

Cardiologists urge adding sexual orientation, gender identity to health records

National associations that represent hospice owe an apology

FDA advisory panel to debate high blood pressure devices

Prior authorization reform is both possible and imperative

A pediatrician calls for Congress to pass the child tax credit deal

entertainment

Wikipedia

hotspot

Wikipedia